オプションチェーンは、Energys Groupの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Energys Groupの市場センチメントを評価します。.

Energys Group (NASDAQ:ENGS) 株価情報, オプションチェーン

Energys Group Ltd provides end-to-end customized solutions and services involving the retrofitting of existing infrastructure to reduce their CO2 emissions. The Company's customers include large national account end-users, including universities, schools, hospitals and electrical distributors in the United Kingdom.

Energys Group Ltd

Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/tesla-china" rel="noreferrer noopener">China-made electric vehicle</a> sales in April dropped 6% year-over-year, extending declines for a seventh month.
Deliveries of China-made Model 3 and Model Y vehicles totaled 58,459 units in April, down 25.8% from March, Reuters reported Wednesday, citing the China Passenger Car Association (CPCA).
Deliveries of China-made Model 3 and Model Y vehicles accounted for exports to markets, including sales in Europe and China.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45238222/teslas-future-hinges-on-china-fsd-analyst-says" rel="noreferrer noopener">Tesla&#8217;s Future Hinges On China FSD: Goldman Sachs</a>
Tesla&#8217;s sales&nbsp;plunged across Europe&nbsp;in April as brand sentiment and political backlash weighed on growth. CEO Elon Musk has acknowledged the challenges of running his business while working with the Department of Government Efficiency (DOGE).&nbsp;
Meanwhile, Tesla&#8217;s Chinese competitors have increased their market share. Tesla stock has lost 28% in stock value year-to-date.
Tesla ramped up efforts to sell into new markets such as&nbsp;India&nbsp;and&nbsp;Saudi Arabia to gain market share akin to its Chinese EV rivals.
Tesla also remains focused on commercializing the affordable version of Model Y in Shanghai in 2026.
Tesla&#8217;s <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44607859/teslas-deliveries-slide-in-q1-amid-production-setbacks-political-backlash" rel="noreferrer noopener">first-quarter deliveries</a> dropped to 336,681 vehicles, down from 386,810 vehicles a year ago, amid production disruptions and weakening global demand. The electric vehicle company produced 362,615 vehicles, down from&nbsp;433,371 a year ago.
Tesla&#8217;s <a target="_blank" href="https://www.benzinga.com/government/regulations/25/03/44330619/tesla-bets-on-low-cost-evs-in-china-after-february-sales-hit-two-year-low" rel="noreferrer noopener">market share in</a> China&#8217;s battery-only EV market fell to 10.4% in 2024 from 11.7% in 2023 as it battled intense competition from Xiaomi (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>). BYD (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) and Xiaomi have launched dozens of models to compete with Tesla.
Price Action: TSLA stock is down 0.31% at $274.50 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45221976/ferrari-beats-q1-holds-2025-outlook-but-warns-tariffs-could-squeeze-profit-margins" target="_blank" rel="noreferrer noopener">Ferrari Beats Q1, Holds 2025 Outlook But Warns Tariffs Could Squeeze Profit Margins</a></li>
</ul>
Image via Shutterstock

Asia

Government

News

Regulations

Emerging Markets

Tech

Media

BYDDF

BYDDY

TSLA

XIACF

XIACY

What Is Going On With Tesla Stock On Wednesday?

RBC Capital analyst Daniel Perlin maintains Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) with a Outperform and lowers the price target from $95 to $93.

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Fidelity National Info, Lowers Price Target to $93

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate InfuSystems Holdings to report an earnings per share (EPS) of $-0.03.
Investors in InfuSystems Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.02, leading to a 3.71% drop in the share price the following trading session.
Here's a look at InfuSystems Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.06</td>
<td>0.06</td>
<td>0.04</td>
<td>0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0.08</td>
<td>0.03</td>
<td>-0.05</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>6.0%</td>
<td>0.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746637750_0.png" alt="eps graph" />
<h3>InfuSystems Holdings Share Price Analysis</h3>
Shares of InfuSystems Holdings were trading at $4.7 as of May 06. Over the last 52-week period, shares are down 36.37%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/INFU/earnings">To track all earnings releases for InfuSystems Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

INFU

InfuSystems Holdings's Earnings Outlook

Goldman Sachs analyst Ryan Nash maintains UWM Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NYSE">UWMC</a>) with a Neutral and lowers the price target from $7 to $6.

UWMC

Goldman Sachs Maintains Neutral on UWM Holdings, Lowers Price Target to $6

RBC Capital analyst Kenneth Lee maintains Federated Hermes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHI#NYSE">FHI</a>) with a Sector Perform and raises the price target from $37 to $43.

RBC Capital Maintains Sector Perform on Federated Hermes, Raises Price Target to $43

Sarepta Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) reported on Tuesday that the first-quarter 2025 loss of&nbsp;$3.42 per share was missing the analyst consensus estimate of&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">losses of 95 cents</a>.
Quarterly revenue came in at $744.86 million,&nbsp;beating the consensus <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45235113/sarepta-therapeutics-announces-first-quarter-2025-financial-results-and-recent-corporate-developme" rel="noreferrer noopener">estimate of&nbsp;$683.36 million</a>.
According to Sarepta CEO Doug Ingram, the company also <a href="https://www.benzinga.com/general/biotech/25/05/45254051/vinay-prasads-appointment-to-fdas-cber-triggers-questions-over-future-of-cell-and-gene-therapy-re" target="_blank" rel="noreferrer noopener">faced headwinds in the quarter</a>. 
&#8220;While we are taking a variety of actions to address and resolve these challenges, we have adjusted our guidance for 2025 to $2.3 billion to $2.6 billion,&#8221; Ingram said. &#8220;The broader biotech market has also faced significant pressure in the first quarter of 2025. Fortunately, as an organization with four life-changing therapies, significant revenue, and a deep pipeline, Sarepta is well-positioned to navigate these chaotic times.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44634689/sareptaroche-suspend-elevidys-gene-therapy-trials-in-europe-after-patient-death" rel="noreferrer noopener">Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death</a>
Guidance: Sarepta revised its 2025 total net product revenues guidance to $2.3-$2.6 billion <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42954480/sarepta-therapeutics-reports-preliminary-fourth-quarter-and-full-year-2024-net-product-revenue" rel="noreferrer noopener">from $2.9-$3.1 billion</a>.
William Blair writes that the revised guidance primarily relates to delayed Elevidys turnaround times.
The time from starting treatment paperwork to actual infusion takes about 1 to 1.5 months longer than expected. This delay is mostly due to stricter screening steps added to protect patients in the larger treatment group, analyst Sami Corwin says. Although the company is trying to speed things up and reduce delays, it expects these early-year trends to continue throughout the rest of the year.
&#8220;We view the miss in total net product and Elevidys revenue as unfortunate and disappointing given the macroeconomic overhangs that have already caused the stock to come under pressure,&#8221; William Blair writes.
The analyst adds that management believes the impact on Elevidys's revenue will be temporary, and expects demand to pick up in the second half of the year, starting in the summer.
<ul>
<li>William Blair maintains <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings" target="_blank" rel="noreferrer noopener">the Outperform rating</a>.</li>
<li>Guggenheim maintains Sarepta with a Buy, lowering the price target from $112 to $98.</li>
<li>Piper Sandler keeps the Overweight rating for Sarepta, lowering the price target from $110 to $70.</li>
<li>Oppenheimer maintains Sarepta with an Outperform, lowering the price target from $184 to $123.</li>
<li>Cantor Fitzgerald reaffirms the company&#8217;s Overweight rating and lowers the price target from $163 to $81.</li>
<li>HC Wainwright maintains Sarepta with a Neutral, lowering the price target from $75 to $40.</li>
<li>Morgan Stanley maintains Sarepta with an Overweight, lowering the price target from $182 to $113.</li>
<li>Needham maintains Sarepta with a Buy and lowers the price target from $183 to $125.</li>
</ul>
Price Action: Sarepta Therapeutics stock is down 19.4% at $37.67 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45258853/geo-missed-q1-targets-on-rising-costs-and-debt-guides-q2-below-street-estimates" target="_blank" rel="noreferrer noopener">GEO Missed Q1 Targets On Rising Costs And Debt, Guides Q2 Below Street Estimates</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Guidance

Health Care

Movers

Trading Ideas

General

SRPT

Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up

<h3>Gainers</h3>
<ul>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) stock rose 26.2% to $0.64 during Wednesday's regular session. The market value of their outstanding shares is at $184.1 million. </li>
<li>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) shares moved upwards by 19.98% to $0.89. The market value of their outstanding shares is at $96.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Mingteng International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEN#NASDAQ">MTEN</a>) shares rose 17.67% to $14.42. The company's market cap stands at $98.5 million. </li>
<li>Denny's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DENN#NASDAQ">DENN</a>) stock increased by 16.11% to $4.54. The company's market cap stands at $232.6 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) shares moved upwards by 15.79% to $23.31. The company's market cap stands at $1.6 billion. As per the press release, Q1 earnings came out today. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) shares increased by 15.69% to $0.37. The company's market cap stands at $12.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>WW International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) stock decreased by 36.0% to $0.51 during Wednesday's regular session. The market value of their outstanding shares is at $40.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Ruanyun Edai Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYET#NASDAQ">RYET</a>) stock fell 24.97% to $5.41. The market value of their outstanding shares is at $182.5 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) shares decreased by 21.38% to $0.19. The company's market cap stands at $76.1 million. The company's, Q1 earnings came out today. </li>
<li>Jeffs Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) stock fell 20.19% to $0.87. The company's market cap stands at $1.6 million. </li>
<li>Lixiang Education Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEH#NASDAQ">LXEH</a>) shares declined by 19.92% to $2.79. The company's market cap stands at $3.2 million. </li>
<li>Greenlane Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares fell 19.24% to $0.01. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DENN

ECDA

GNLN

JFBR

LXEH

MTEN

NWTN

PRPL

QVCGA

RYET

SHOO

12 Consumer Discretionary Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 25.4% to $189.28 during Wednesday's regular session. The company's market cap stands at $2.4 billion. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock increased by 23.37% to $0.4. The company's market cap stands at $4.3 million. </li>
<li>Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) stock moved upwards by 20.66% to $11.47. The market value of their outstanding shares is at $5.6 billion. The company's, Q1 earnings came out today. </li>
<li>Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) shares moved upwards by 19.47% to $13.56. The market value of their outstanding shares is at $587.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock rose 18.02% to $2.03. The company's market cap stands at $9.6 million. </li>
<li>Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock moved upwards by 17.77% to $69.94. The market value of their outstanding shares is at $8.6 billion. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock declined by 44.6% to $0.09 during Wednesday's regular session. The market value of their outstanding shares is at $2.4 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock fell 41.43% to $0.8. The company's market cap stands at $2.2 million. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 36.46% to $4.62. The company's market cap stands at $425.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) shares decreased by 29.61% to $1.07. The company's market cap stands at $2.8 million. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) shares decreased by 26.03% to $0.7. The market value of their outstanding shares is at $2.6 million. </li>
<li>Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) stock decreased by 24.03% to $3.39. The market value of their outstanding shares is at $1.3 billion. As per the news, the Q1 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBNX

ELAN

HALO

HEPA

KTTA

MYGN

PHIO

TOVX

12 Health Care Stocks Moving In Wednesday's Intraday Session

Goldman Sachs analyst George Tong maintains UL Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>) with a Neutral and raises the price target from $57 to $63.

Goldman Sachs Maintains Neutral on UL Solutions, Raises Price Target to $63

<h3>Gainers</h3>
<ul>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) shares rose 63.0% to $7.66 during Wednesday's regular session. The market value of their outstanding shares is at $11.7 million. </li>
<li>OneConstruction Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEG#NASDAQ">ONEG</a>) stock rose 55.44% to $3.14. The company's market cap stands at $40.8 million. </li>
<li>Concorde Intl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIGL#NASDAQ">CIGL</a>) stock rose 46.59% to $6.45. The market value of their outstanding shares is at $142.7 million. </li>
<li>GrafTech International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) shares rose 34.14% to $0.79. The company's market cap stands at $204.3 million. </li>
<li>Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) stock increased by 30.45% to $6.58. The company's market cap stands at $1.4 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Babcock &amp; Wilcox Enterprises, Inc. 6.50% Senior Notes due 2026 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWNB#NYSE">BWNB</a>) shares moved upwards by 21.76% to $9.57. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) stock declined by 58.0% to $0.15 during Wednesday's regular session. The company's market cap stands at $4.6 million. </li>
<li>Vestis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) stock fell 37.61% to $5.43. The market value of their outstanding shares is at $716.0 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Costamare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) stock decreased by 23.6% to $7.04. The market value of their outstanding shares is at $845.1 million. </li>
<li>New Century Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCEW#NASDAQ">NCEW</a>) stock decreased by 21.98% to $1.74. The company's market cap stands at $37.4 million. </li>
<li>MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) shares declined by 14.45% to $10.25. The company's market cap stands at $1.3 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>ConnectM Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) stock fell 14.33% to $0.56. The company's market cap stands at $16.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BWNB

CIGL

CMRE

CNTM

EOSE

GPUS

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

NCEW

ONEG

VSTE

VSTS

12 Industrials Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Porch Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) stock rose 58.4% to $10.04 during Wednesday's regular session. The market value of their outstanding shares is at $1.0 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Gen Digital Inc. - Contingent Value Rights (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENVR#NASDAQ">GENVR</a>) stock rose 30.74% to $6.63. </li>
<li>Kimball Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KE#NASDAQ">KE</a>) shares moved upwards by 21.04% to $17.81. The market value of their outstanding shares is at $439.4 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Nortech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) stock increased by 20.15% to $11.04. The company's market cap stands at $30.4 million. </li>
<li>Atomera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) stock rose 15.32% to $5.85. The market value of their outstanding shares is at $179.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Digital Turbine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) stock moved upwards by 15.24% to $3.56. The company's market cap stands at $373.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>FOXO Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#AMEX">FOXO</a>) shares decreased by 50.7% to $0.79 during Wednesday's regular session. The company's market cap stands at $2.8 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock decreased by 24.72% to $2.65. The company's market cap stands at $26.4 million. </li>
<li>CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) stock fell 20.66% to $20.11. The market value of their outstanding shares is at $226.8 million. As per the press release, Q1 earnings came out today. </li>
<li>CEVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NASDAQ">CEVA</a>) stock decreased by 19.6% to $21.29. The company's market cap stands at $509.0 million. The company's, Q1 earnings came out today. </li>
<li>Synchronoss Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCR#NASDAQ">SNCR</a>) shares decreased by 17.26% to $8.54. The company's market cap stands at $98.1 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Diginex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) shares fell 17.24% to $63.0. The company's market cap stands at $1.4 billion. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APPS

ATOM

CEVA

DGNX

FOXO

GENVR

MLGO

NSYS

PMTS

PRCH

SNCR

12 Information Technology Stocks Moving In Wednesday's Intraday Session

RBC Capital analyst Brad Erickson reiterates DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Outperform and maintains $230 price target.

Reiteration

DASH

RBC Capital Reiterates Outperform on DoorDash, Maintains $230 Price Target

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) shares are trading higher Wednesday after the company reported better-than-expected first-quarter financial results on Monday after <a href="https://www.benzinga.com//node/45237261">the market closed.</a>
What To Know: The company reported adjusted earnings per share of 96 cents, beating the consensus estimate of 94 cents. In addition, AMD reported sales of $7.44 billion, beating the consensus estimate of $7.13 billion and representing a 36% year-over-year growth.
The company provided a segment breakdown, reporting $3.7 billion in Data Center revenue, $2.9 billion from its Client and Gaming segment and $823 million from its Embedded segment. Data Center revenue rose 57% year-over-year, while Client and Gaming revenue climbed 68%.
&#8220;We delivered an outstanding start to 2025 as year-over-year growth accelerated for the fourth consecutive quarter driven by strength in our core businesses and expanding data center and AI momentum,&#8221; said Dr. Lisa Su, AMD chair and CEO. 
&#8220;Despite the dynamic macro and regulatory environment, our&nbsp;first quarter&nbsp;results and&nbsp;second quarter&nbsp;outlook&nbsp;highlight the strength of our differentiated product portfolio and consistent execution positioning us well for strong growth in 2025.&#8221;
Outlook: The company sees second-quarter sales from $7.10 billion to $7.70 billion, versus the consensus estimate of $7.24 billion.
Analyst Changes: Following the earnings report, multiple analysts issued price target adjustments.
<ul>
<li>Raymond James analyst Srini Pajjuri reiterated an Outperform rating on AMD and lowered the price target from&nbsp;$150&nbsp;to&nbsp;$120.</li>
<li>UBS analyst Timothy Arcuri maintained a Buy rating on AMD and lowered the price target from&nbsp;$155&nbsp;to&nbsp;$150.</li>
<li>Piper Sandler analyst Harsh Kumar reiterated an Overweight rating on AMD and lowered the price target from&nbsp;$140&nbsp;to&nbsp;$125.</li>
<li>Loop Capital analyst Gary Mobley maintained a Buy rating on AMD and lowered the price target from&nbsp;$175&nbsp;to&nbsp;$140.</li>
</ul>
See Also: <a href="https://www.benzinga.com/25/05/45259638/celanese-analysts-boost-their-forecasts-after-upbeat-q1-results">Celanese Analysts Boost Their Forecasts After Upbeat Q1 Results</a>
AMD Price Action: At the time of writing, AMD stock is trading 0.65% higher at $99.22, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: Courtesy of Advanced Micro Devices, Inc.

What's Going On With Advanced Micro Devices Stock Wednesday?

Ready Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RC#NYSE">RC</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-08. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Ready Capital to report an earnings per share (EPS) of $0.27.
Ready Capital bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
Last quarter the company missed EPS by $0.24, which was followed by a 2.37% drop in the share price the next day.

<img src="https://www.benzinga.com/files/images/story/2025/1746637479_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Ready Capital were trading at $4.36 as of May 06. Over the last 52-week period, shares are down 48.67%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/RC/earnings">To track all earnings releases for Ready Capital visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of Ready Capital's Earnings

RBC Capital analyst Matthew Hedberg maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Outperform and maintains $119 price target.

DDOG

RBC Capital Maintains Outperform on Datadog, Maintains $119 Price Target

Goldman Sachs analyst Brian Lee maintains Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) with a Buy and raises the price target from $5 to $6.

SHLS

Goldman Sachs Maintains Buy on Shoals Technologies Gr, Raises Price Target to $6

Deep-pocketed investors have adopted a bullish approach towards Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DUOL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Duolingo. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 56% leaning bullish and 25% bearish. Among these notable options, 8 are puts, totaling $356,837, and 8 are calls, amounting to $1,648,934.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $400.0 to $700.0 for Duolingo over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Duolingo's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Duolingo's whale trades within a strike price range from $400.0 to $700.0 in the last 30 days. 
<h3>Duolingo Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746637363_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$108.4</td>
<td>$108.4</td>
<td>$108.4</td>
<td>$400.00</td>
<td>$1.1M</td>
<td align="right">137</td>
<td align="right">0</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$11.4</td>
<td>$10.2</td>
<td>$11.16</td>
<td>$520.00</td>
<td>$157.5K</td>
<td align="right">238</td>
<td align="right">175</td>
</tr>
<tr>
<td>DUOL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$103.5</td>
<td>$99.2</td>
<td>$100.4</td>
<td>$600.00</td>
<td>$80.3K</td>
<td align="right">8</td>
<td align="right">0</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$11.6</td>
<td>$11.4</td>
<td>$11.4</td>
<td>$520.00</td>
<td>$75.6K</td>
<td align="right">238</td>
<td align="right">242</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$12.1</td>
<td>$11.6</td>
<td>$11.6</td>
<td>$520.00</td>
<td>$66.1K</td>
<td align="right">238</td>
<td align="right">299</td>
</tr>
</tbody>
</table>

<h3>About Duolingo</h3>
Duolingo Inc is a technology company that develops a mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test, and In-App Purchases.
Following our analysis of the options activities associated with Duolingo, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Duolingo</h3>
<ul>
<li>Currently trading with a volume of 487,862, the DUOL's price is up by 1.28%, now at $496.81. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 91 days.</li>
</ul>
<h3>Expert Opinions on Duolingo</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $446.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Duolingo, which currently sits at a price target of $375. 
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Duolingo with a target price of $480. 
&#x2A; Consistent in their evaluation, an analyst from Scotiabank keeps a Sector Outperform rating on Duolingo with a target price of $405. 
&#x2A; Consistent in their evaluation, an analyst from Scotiabank keeps a Sector Outperform rating on Duolingo with a target price of $470. 
&#x2A; An analyst from UBS persists with their Buy rating on Duolingo, maintaining a target price of $500. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Duolingo options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

DUOL

This Is What Whales Are Betting On Duolingo

Financial giants have made a conspicuous bearish move on Apple. Our analysis of options history for Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) revealed 102 unusual trades.
Delving into the details, we found 37% of traders were bullish, while 48% showed bearish tendencies. Out of all the trades we spotted, 54 were puts, with a value of $3,786,891, and 48 were calls, valued at $5,294,435.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $165.0 to $230.0 for Apple over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Apple's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Apple's whale activity within a strike price range from $165.0 to $230.0 in the last 30 days. 
<h3>Apple Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746637357_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/09/25</td>
<td>$3.05</td>
<td>$2.99</td>
<td>$2.99</td>
<td>$195.00</td>
<td>$1.3M</td>
<td>2.0K</td>
<td>30.9K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$9.25</td>
<td>$9.2</td>
<td>$9.2</td>
<td>$200.00</td>
<td>$920.2K</td>
<td>4.6K</td>
<td>1.7K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$20.3</td>
<td>$20.25</td>
<td>$20.25</td>
<td>$230.00</td>
<td>$575.1K</td>
<td>4.3K</td>
<td>1.5K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$20.35</td>
<td>$20.3</td>
<td>$20.3</td>
<td>$230.00</td>
<td>$243.6K</td>
<td>4.3K</td>
<td>1.5K</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.75</td>
<td>$9.65</td>
<td>$9.65</td>
<td>$195.00</td>
<td>$150.5K</td>
<td>14.4K</td>
<td>2.4K</td>
</tr>
</tbody>
</table>

<h3>About Apple</h3>
Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.
Following our analysis of the options activities associated with Apple, we pivot to a closer look at the company's own performance.
<h3>Where Is Apple Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 30,736,450, the AAPL's price is down by -1.55%, now at $195.44. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 85 days.</li>
</ul>
<h3>What Analysts Are Saying About Apple</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $189.7.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Jefferies lowers its rating to Underperform with a new price target of $170. 
&#x2A; An analyst from Jefferies has elevated its stance to Hold, setting a new price target at $167. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $225. 
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Underweight rating for Apple, targeting a price of $170. 
&#x2A; Maintaining their stance, an analyst from Loop Capital continues to hold a Hold rating for Apple, targeting a price of $215. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Apple options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

AAPL

Apple Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bullish stance on Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with QCOM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Qualcomm.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 42%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $276,012, and 7 are calls, for a total amount of $470,485.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $145.0 for Qualcomm during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Qualcomm's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Qualcomm's significant trades, within a strike price range of $70.0 to $145.0, over the past month.
<h3>Qualcomm Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746637351_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/09/25</td>
<td>$6.9</td>
<td>$5.3</td>
<td>$6.0</td>
<td>$136.00</td>
<td>$120.0K</td>
<td align="right">530</td>
<td align="right">201</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$26.85</td>
<td>$26.4</td>
<td>$26.85</td>
<td>$125.00</td>
<td>$85.9K</td>
<td align="right">648</td>
<td align="right">0</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$34.7</td>
<td>$34.25</td>
<td>$34.25</td>
<td>$115.00</td>
<td>$68.5K</td>
<td align="right">173</td>
<td align="right">91</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$34.45</td>
<td>$34.3</td>
<td>$34.3</td>
<td>$115.00</td>
<td>$58.3K</td>
<td align="right">173</td>
<td align="right">17</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$27.5</td>
<td>$27.35</td>
<td>$27.35</td>
<td>$125.00</td>
<td>$51.9K</td>
<td align="right">648</td>
<td align="right">82</td>
</tr>
</tbody>
</table>

<h3>About Qualcomm</h3>
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.
Following our analysis of the options activities associated with Qualcomm, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Qualcomm</h3>
<ul>
<li>With a trading volume of 3,675,103, the price of QCOM is up by 2.32%, reaching $143.14.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 84 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Qualcomm</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $185.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Susquehanna persists with their Positive rating on Qualcomm, maintaining a target price of $190. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Qualcomm with a target price of $216. 
&#x2A; An analyst from Rosenblatt has decided to maintain their Buy rating on Qualcomm, which currently sits at a price target of $225. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Underweight rating on Qualcomm, which currently sits at a price target of $140. 
&#x2A; An analyst from Loop Capital has decided to maintain their Hold rating on Qualcomm, which currently sits at a price target of $155. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Qualcomm, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

QCOM

Qualcomm's Options Frenzy: What You Need to Know

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Outperform and lowers the price target from $82 to $80.

CYTK

RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $80

Press Releases

Energys Group Announces Pricing of $10.125 Million Initial Public Offering and Nasdaq Listing

Offerings

American Trust Investment Services Serves as Sole Underwriter for Energys Group Ltd IPO

Energys Group Announces Closing of $10.125 Million Initial Public Offering

Energys Group Signs Memorandum of Understanding to Acquire 49% Interest in Energy Services Company Operating in Hong Kong

Comments

Energys Group

Energys Group (ENGS) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル